Citations 1
Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G. , Usmani, Saad Zafar, Bensinger, William, Dubin, Franck , Liu, Qianying , Vitse, Olivier , Mıkhael, Joseph , Richardson, Paul Gerard Guy , Usmani, Saad Zafar, Raje, Noopur , Anderson, Kenneth C.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8038-8038
